Aetna launched a pilot program in Florida and New Jersey where select ASCs will be reimbursed for using Exparel to incentivize non-opioid therapies for postsurgical pain management.
Here are the key details to know:
1. Exparel is a bupivicaine liposome injectable suspension surgeons can use as part of a multimodal approach to pain management for surgical cases. The injection can help patients with prolonged pain control that can help reduce the need for opioids.
2. In 2017, the company began reimbursing for Exparel for use in select impacted wisdom tooth extractions and has decided to expand the program to ASCs.
3. Aetna also recently updated its online provider directory to help members identify surgeons trained to administer Exparel.
To learn more about the new CMS rule as well as hear from ASC owners, administrators and leaders in ASC billing and coding on their experiences with Exparel, register for this webinar titled "CMS Reimburses Non-Opioid Postsurgical Pain Management in the ASC: Review of the New CMS Rules and Opportunity for ASCs" on Dec. 4, from 12:00 p.m. to 1:00 p.m.